Interim INTREPID trial safety results trend toward minimal radiation-induced changes

NEW ORLEANS ā€“ Interim safety data for the INTREPID trial thus far yield a 15% rate of radiation-induced microvascular changes in patients at 3 years, according to a presenter. ā€œIn this previously treated patient population, the INTREPID trial met its primary superiority outcome with a 33% reduction at 1 year in the number of Lucentis injections, and this effect persisted out to 24 months with a 25% reduction,ā€ Darius M. Moshfeghi, MD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Full Story ā†’